Quest Partners LLC Has $113,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Quest Partners LLC lifted its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 914.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,020 shares of the company’s stock after acquiring an additional 9,934 shares during the quarter. Quest Partners LLC’s holdings in iTeos Therapeutics were worth $113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ITOS. Vanguard Group Inc. boosted its holdings in shares of iTeos Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock worth $20,468,000 after acquiring an additional 9,660 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of iTeos Therapeutics by 4.9% in the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in iTeos Therapeutics by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock worth $1,799,000 after buying an additional 5,409 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in iTeos Therapeutics by 35.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock worth $178,000 after buying an additional 3,172 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its holdings in iTeos Therapeutics by 8.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company’s stock worth $1,952,000 after buying an additional 10,787 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Up 0.1 %

ITOS stock opened at $8.55 on Friday. The business’s fifty day moving average is $9.13 and its 200-day moving average is $13.64. The company has a market cap of $312.33 million, a P/E ratio of -2.71 and a beta of 1.39. iTeos Therapeutics, Inc. has a twelve month low of $7.54 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Research analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 12.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ITOS has been the topic of several research reports. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a report on Friday, November 15th. Finally, Wells Fargo & Company initiated coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective on the stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.